Abstract:BACKGROUND:Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality. Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.METHODS:The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals, and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.RESULTS:All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR. MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P < 0.0001). MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P = 0.260). MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P = 0.001). There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell carcinoma patients (P < 0.0001). In receiver operating characteristic curve (ROC) analysis, low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects. High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects. High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma. The miR-150 level was significantly associated with distant metastasis (P = 0.014).CONCLUSIONS:It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.

Clinical Utility of Plasma Mirna-155 and Mirna-625 Detection in the Diagnosis of Non-Small Cell Lung Cancer

The Role of Plasma Mirnas in the Diagnosis of Pulmonary Nodules

Plasma Mir‐1247‐5p, Mir‐301b‐3p and Mir‐105‐5p As Potential Biomarkers for Early Diagnosis of Non‐small Cell Lung Cancer

Increased Plasma Mirna-30A As a Biomarker for Non-Small Cell Lung Cancer.

Expression Level of Serum Mirna-22 and Its Clinical Significance in Patients with Lung Cancer

Application of plasma circulation microRNA-126 to diagnosis of non-small cell lung cancer

A Plasma Mirna-Based Classifier for Small Cell Lung Cancer Diagnosis

Five Micrornas in Plasma As Novel Biomarkers for Screening of Early-Stage Non-Small Cell Lung Cancer

Identification of Plasma miRNA-21 as a Biomarker for Diagnosis and Chemotherapy Prognosis in Non-Small Cell Lung Cancer

Altered Mir-143 and Mir-150 Expressions in Peripheral Blood Mononuclear Cells for Diagnosis of Non-Small Cell Lung Cancer.

Plasma Mir-92A-2 As a Biomarker for Small Cell Lung Cancer.

Identification of miRNA Biomarkers for Non-small Cell Lung Cancer using Microarray Datasets and Bioinformatics Analysis

Identification of Plasma Microrna-21 As a Biomarker for Early Detection and Chemosensitivity of Non-Small Cell Lung Cancer

CLINICAL EVALUATION OF A PANEL OF CIRCULATING MICRORNAS IN NONSMALL CELL LUNG CANCER

Circulating Plasma Mirnas As Potential Biomarkers of Non-Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling

Circulating MicroRNA Panel As a Diagnostic Marker for Hepatocellular Carcinoma

Identification of Serum Mirnas by Nano-Quantum Dots Microarray As Diagnostic Biomarkers for Early Detection of Non-Small Cell Lung Cancer

Diagnostic Value of Serum Mir197 and Mir145 in Non-Small Cell Lung Cancer

Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer

Evaluation of Serum-Paired Mirna Ratios for Early Diagnosis of Non-Small Cell Lung Cancer Using Quantum Dot-Based Suspension Array

Evaluation of Plasma Mir-21 and Mir-152 As Diagnostic Biomarkers for Common Types of Human Cancers